Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine
Objectives This study aimed to evaluate the prognostic significance of the revised European LeukemiaNet (ELN)−2022 risk stratification model for 123 elderly acute myeloid leukemia (AML) patients treated with decitabine chemotherapy.Results Based on the ELN-2022 risk stratification, 15 (12.2%), 51 (4...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2324417 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850246546718720000 |
|---|---|
| author | Mihee Kim Seo-Yeon Ahn TaeHyung Kim Sung-Hoon Jung Ga-Young Song Deok-Hwan Yang Je-Jung Lee Mi Yeon Kim Ju Heon Park Myung-Geun Shin Jae-Sook Ahn Hyeoung-Joon Kim Dennis Dong Hwan Kim |
| author_facet | Mihee Kim Seo-Yeon Ahn TaeHyung Kim Sung-Hoon Jung Ga-Young Song Deok-Hwan Yang Je-Jung Lee Mi Yeon Kim Ju Heon Park Myung-Geun Shin Jae-Sook Ahn Hyeoung-Joon Kim Dennis Dong Hwan Kim |
| author_sort | Mihee Kim |
| collection | DOAJ |
| description | Objectives This study aimed to evaluate the prognostic significance of the revised European LeukemiaNet (ELN)−2022 risk stratification model for 123 elderly acute myeloid leukemia (AML) patients treated with decitabine chemotherapy.Results Based on the ELN-2022 risk stratification, 15 (12.2%), 51 (41.5%), and 57 (46.3%) patients were classified as having favorable, intermediate, and high-risk AML, respectively. In comparison with the ELN-2017 risk stratification, the ELN-2022 risk stratification re-assigned 26 (21.1%) and three (2.4%) patients to the adverse and favorable risk groups, respectively. Survival analysis revealed distinctive overall survival (OS) outcomes among the ELN-2022 risk groups (6-month OS rate: 73.3%, 52.9%, and 47.7% for favorable, intermediate, and adverse risk, respectively; P = 0.101), with a parallel trend observed in the event-free survival (EFS) (6-month EFS rate: 73.3%, 52.9%, and 45.6% for favorable, intermediate, and adverse risk, respectively; P = 0.049). Notably, both OS and EFS in the favorable risk group were significantly superior in comparison to that of the adverse risk group (OS: P = 0.040, EFS: P = 0.030). Although the ELN-2022 C-index (0.559) was greater than the ELN-2017 C-index (0.539), the result was not statistically significant (P = 0.059). Based on the event net reclassification index, we consistently observed significant improvements in the ELN-2022 risk stratification for overall survival (0.21 at 6 months).Conclusion In conclusion, the revised ELN-2022 risk stratification model may have improved the risk classification of elderly AML patients treated with hypomethylating agents compared to the ELN-2017 risk stratification model. |
| format | Article |
| id | doaj-art-dd0b63ffec98445ba69d2626086a7637 |
| institution | OA Journals |
| issn | 1607-8454 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj-art-dd0b63ffec98445ba69d2626086a76372025-08-20T01:59:09ZengTaylor & Francis GroupHematology1607-84542024-12-0129110.1080/16078454.2024.2324417Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabineMihee Kim0Seo-Yeon Ahn1TaeHyung Kim2Sung-Hoon Jung3Ga-Young Song4Deok-Hwan Yang5Je-Jung Lee6Mi Yeon Kim7Ju Heon Park8Myung-Geun Shin9Jae-Sook Ahn10Hyeoung-Joon Kim11Dennis Dong Hwan Kim12Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Jeollanam-do, Republic of KoreaHematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Jeollanam-do, Republic of KoreaDepartment of Computer Science, University of Toronto, Toronto, CanadaHematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Jeollanam-do, Republic of KoreaHematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Jeollanam-do, Republic of KoreaHematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Jeollanam-do, Republic of KoreaHematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Jeollanam-do, Republic of KoreaGenomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of KoreaGenomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of KoreaGenomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of KoreaHematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Jeollanam-do, Republic of KoreaHematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Jeollanam-do, Republic of KoreaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, CanadaObjectives This study aimed to evaluate the prognostic significance of the revised European LeukemiaNet (ELN)−2022 risk stratification model for 123 elderly acute myeloid leukemia (AML) patients treated with decitabine chemotherapy.Results Based on the ELN-2022 risk stratification, 15 (12.2%), 51 (41.5%), and 57 (46.3%) patients were classified as having favorable, intermediate, and high-risk AML, respectively. In comparison with the ELN-2017 risk stratification, the ELN-2022 risk stratification re-assigned 26 (21.1%) and three (2.4%) patients to the adverse and favorable risk groups, respectively. Survival analysis revealed distinctive overall survival (OS) outcomes among the ELN-2022 risk groups (6-month OS rate: 73.3%, 52.9%, and 47.7% for favorable, intermediate, and adverse risk, respectively; P = 0.101), with a parallel trend observed in the event-free survival (EFS) (6-month EFS rate: 73.3%, 52.9%, and 45.6% for favorable, intermediate, and adverse risk, respectively; P = 0.049). Notably, both OS and EFS in the favorable risk group were significantly superior in comparison to that of the adverse risk group (OS: P = 0.040, EFS: P = 0.030). Although the ELN-2022 C-index (0.559) was greater than the ELN-2017 C-index (0.539), the result was not statistically significant (P = 0.059). Based on the event net reclassification index, we consistently observed significant improvements in the ELN-2022 risk stratification for overall survival (0.21 at 6 months).Conclusion In conclusion, the revised ELN-2022 risk stratification model may have improved the risk classification of elderly AML patients treated with hypomethylating agents compared to the ELN-2017 risk stratification model.https://www.tandfonline.com/doi/10.1080/16078454.2024.2324417Acute myeloid leukemiaEuropean LeukemiaNetelderly patientsdecitabine |
| spellingShingle | Mihee Kim Seo-Yeon Ahn TaeHyung Kim Sung-Hoon Jung Ga-Young Song Deok-Hwan Yang Je-Jung Lee Mi Yeon Kim Ju Heon Park Myung-Geun Shin Jae-Sook Ahn Hyeoung-Joon Kim Dennis Dong Hwan Kim Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine Hematology Acute myeloid leukemia European LeukemiaNet elderly patients decitabine |
| title | Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine |
| title_full | Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine |
| title_fullStr | Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine |
| title_full_unstemmed | Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine |
| title_short | Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine |
| title_sort | prognostic analysis according to european leukemianet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine |
| topic | Acute myeloid leukemia European LeukemiaNet elderly patients decitabine |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2024.2324417 |
| work_keys_str_mv | AT miheekim prognosticanalysisaccordingtoeuropeanleukemianet2022riskstratificationforelderlypatientswithacutemyeloidleukemiatreatedwithdecitabine AT seoyeonahn prognosticanalysisaccordingtoeuropeanleukemianet2022riskstratificationforelderlypatientswithacutemyeloidleukemiatreatedwithdecitabine AT taehyungkim prognosticanalysisaccordingtoeuropeanleukemianet2022riskstratificationforelderlypatientswithacutemyeloidleukemiatreatedwithdecitabine AT sunghoonjung prognosticanalysisaccordingtoeuropeanleukemianet2022riskstratificationforelderlypatientswithacutemyeloidleukemiatreatedwithdecitabine AT gayoungsong prognosticanalysisaccordingtoeuropeanleukemianet2022riskstratificationforelderlypatientswithacutemyeloidleukemiatreatedwithdecitabine AT deokhwanyang prognosticanalysisaccordingtoeuropeanleukemianet2022riskstratificationforelderlypatientswithacutemyeloidleukemiatreatedwithdecitabine AT jejunglee prognosticanalysisaccordingtoeuropeanleukemianet2022riskstratificationforelderlypatientswithacutemyeloidleukemiatreatedwithdecitabine AT miyeonkim prognosticanalysisaccordingtoeuropeanleukemianet2022riskstratificationforelderlypatientswithacutemyeloidleukemiatreatedwithdecitabine AT juheonpark prognosticanalysisaccordingtoeuropeanleukemianet2022riskstratificationforelderlypatientswithacutemyeloidleukemiatreatedwithdecitabine AT myunggeunshin prognosticanalysisaccordingtoeuropeanleukemianet2022riskstratificationforelderlypatientswithacutemyeloidleukemiatreatedwithdecitabine AT jaesookahn prognosticanalysisaccordingtoeuropeanleukemianet2022riskstratificationforelderlypatientswithacutemyeloidleukemiatreatedwithdecitabine AT hyeoungjoonkim prognosticanalysisaccordingtoeuropeanleukemianet2022riskstratificationforelderlypatientswithacutemyeloidleukemiatreatedwithdecitabine AT dennisdonghwankim prognosticanalysisaccordingtoeuropeanleukemianet2022riskstratificationforelderlypatientswithacutemyeloidleukemiatreatedwithdecitabine |